Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by HARLEYDAVIDSON21on Sep 29, 2014 5:57pm
182 Views
Post# 22980855

Dirk's Tweet .................Dirk Haussecker @RNAiAnalyst

Dirk's Tweet .................Dirk Haussecker @RNAiAnalyst

OK, time to start paying a little attention to $TKMR again...monster, possibly make-or-break month to come.

Well, the Xman only half-way agrees with him. October is a make-or-make month, with very little downside risk at this point in time.

Imagine...we are in possession of the ONLY effective doses of a life-saving therapy for an epidemic that kills effectively and indiscriminately.

We have one FDA licensed drug being currently sold under the brand-name Marqibo. https://www.marqibo.com/

We have drugs in human testing that could cure or at least effectively treat amyloidosis (ALN-TTR02), various cancers (TKM-PLK1), Ebola (TKM-EBOV), Hepatitis B (TKM-HBV), Marburg (TKM-Marburg) or any other virus known-to-man.

We have another development deal with the largest Agricultural Research Company as well (Monsanto).

We are expanding operations to Seattle, Washington and have at least one drug being mysteriously tested in China by Asceltis (ALN-VSP).

Helz belz, I'll toot our horn if Burnaby won't! LOL
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse